Valganciclovir is activated by HSV-thymidine kinase (from the GEN2 vector) to ganciclovir triphosphate, which is incorporated into DNA and inhibits DNA polymerases, causing chain termination and death of HSV-TK–transduced cells. Expression of DNA polymerase alpha alone does not confer selective killing by this drug.